Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of urate LowEring Agent Febuxostat in Chronic Heart Failure patients with hyperuricemia

Trial Profile

Effect of urate LowEring Agent Febuxostat in Chronic Heart Failure patients with hyperuricemia

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Mar 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Febuxostat (Primary)
  • Indications Chronic heart failure; Hyperuricaemia
  • Focus Therapeutic Use
  • Acronyms LEAF-CHF
  • Most Recent Events

    • 28 Feb 2019 Status changed from recruiting to completed.
    • 05 Mar 2015 According to the the University Hospital Medical Information Network - Japan record, status changed from not yet recruiting to recruiting.
    • 01 Aug 2014 Planned initiation date changed from 1 Apr 2014 to 1 Aug 2014 as reported by University Hospital Medical Information Network - Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top